APA (7th ed.) Citation

M, T., YA, A., M, A., O, A., A, M., M, T., . . . M, A. (2025). The Efficacy and Safety of GLP-1 RAs in the Modification of Cardiovascular Morbidity in Patients with Obesity Without Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials Involving 32,884 Patients. American journal of cardiovascular drugs : drugs, devices, and other interventions, 25(4), 491. https://doi.org/10.1007/s40256-025-00726-z

Chicago Style (17th ed.) Citation

M, Tanashat, Al-Ajlouni YA, Abuelazm M, Altobaishat O, Manasrah A, Turkmani M, Khan U, and Abouzid M. "The Efficacy and Safety of GLP-1 RAs in the Modification of Cardiovascular Morbidity in Patients with Obesity Without Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials Involving 32,884 Patients." American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 25, no. 4 (2025): 491. https://doi.org/10.1007/s40256-025-00726-z.

MLA (9th ed.) Citation

M, Tanashat, et al. "The Efficacy and Safety of GLP-1 RAs in the Modification of Cardiovascular Morbidity in Patients with Obesity Without Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials Involving 32,884 Patients." American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, vol. 25, no. 4, 2025, p. 491, https://doi.org/10.1007/s40256-025-00726-z.